BeMob Tracking Pixel
No Result
View All Result
No Result
View All Result
No Result
View All Result

You might also like

━ Disseminated on behalf of Rocket Doctor AI Inc. 

The healthcare system is broken. 
AI is the only viable fix.
One physician-led company is already building it.

CSE AIDR

OTC AIRDF

WKN A41FSK

The system is failing. The numbers don't lie.

Healthcare in North America is running on fumes.

Costs are spiraling out of control, access is shrinking, and the quality

of care that have nothing to do with medicine; where they live, how long they can wait, and whether their doctor has five minutes or fifty seconds to spend with them.
The statistics paint a picture that should alarm every investor, every patient, and every policymaker paying attention.

Cost of misdiagnosis

$100B+

US healthcare system1

Physician time on admin

~40%

Of working hours11

Misdiagnosis costs the US healthcare system over $100 billion annually, not because doctors lack intelligence, but because they are overwhelmed, under-supported, and drowning in data from too many sources simultaneously.[1]


Physicians spend approximately 40% of their working hours on administrative tasks, documentation, billing, coding, referrals, rather than actually caring for patients.[2]


Millions of Americans are affected by diagnostic errors every year, creating a patient safety crisis that the medical system has struggled to address with the tools currently available to it.


And underlying all of it is a supply crisis that no amount of medical school expansion will solve in the near term: there are simply fewer doctors available to see more patients in shorter visits. Burnout is accelerating that trend. The pipeline of new physicians takes a decade to build. The problem is happening now.


The traditional response, build more hospitals, train more doctors, expand insurance networks, is too slow, too expensive, and too linear for the scale of the challenge. The world needs a fundamentally different approach.

That approach is AI-powered healthcare infrastructure built by the people who actually understand what happens at the clinical frontline. And that is precisely what Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has spent years quietly building.

A market opportunity
that is impossible to ignore.

The global digital health market is one of the fastest-growing sectors in technology.

AI-powered healthcare, specifically, is at an inflection point where the

convergence of machine learning capability, clinical data availability, and healthcare system pressure is creating a window of opportunity that rarely opens twice.

AI in healthcare

$22.4B → $208.2B

2023 → 2030. CAGR of 37%+.[3]
Telemedicine

$380B+

Global market by 2030[4]

The global AI in healthcare market was valued at approximately $22.4 billion in 2023 and is projected to reach $208.2 billion by 2030, growing at a compound annual growth rate of over 37%.[3]

 

The global telemedicine market alone is expected to surpass $380 billion by 2030, driven by consumer demand for accessible care, physician adoption of virtual platforms, and the irreversible shift in payer acceptance of telehealth services accelerated by the COVID-19 pandemic.[4]

 

But here is what most investors miss when looking at healthcare AI: the market is not just large.

 

It is structurally underserved by technology that actually works in a clinical context.

 

Most AI tools being thrown at healthcare problems were not built by clinicians, do not reflect the complexity of real diagnostic workflows, and fail to integrate into the systems that physicians and patients actually use.

 

The gap between the AI tools that exist and the AI tools that healthcare actually needs is enormous. And that gap is exactly where Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has designed its competitive moat to address.

Rocket Doctor AI: Where clinical expertise meets intelligent technology.

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is not a technology company that decided to enter healthcare. It is a healthcare company that built technology, a critical distinction that shapes everything about how the platform was designed, how it performs, and why it has earned the trust of physicians, health systems, and patients across North America.


The company operates through two interconnected entities: Rocket Doctor Inc., the Canadian operating company founded and led by Dr. William Cherniak MD MPH CCFP(EM), and Rocket Doctor AI Inc., the AI and technology division led by CEO Dr. Essam Hamza MD CCFP.


Together, they have built a comprehensive physician-built AI healthcare platform.


The guiding principle behind every product decision is deceptively simple: build AI that thinks like a doctor, because the people who built it are doctors.

The Global Library of Medicine: The Proprietary Brain Behind Everything

At the core of the Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) technology stack sits the Global Library of Medicine, or GLM, a proprietary AI engine.

The GLM has been in development since 2016. Over the course of nearly a decade, it has been built with input from hundreds of clinicians globally, accumulating over 25,000 hours of clinical expertise embedded directly into its algorithms and logic systems.

It has undergone more than 10,000 expert medical reviews, a level of clinical validation that distinguishes it from the general-purpose large language models that most technology companies are attempting to adapt for healthcare use.

In development since

2016

Nearly a decade of clinical refinement
Clinician-hours embedded

25,000+

From hundreds of clinicians, globally

What the GLM can do, in practical terms, is extraordinary:

━
Diagnose more than 1,000 diseases and assess more than 17,000 symptoms and risk factors in real time[5]
━
Suggest appropriate laboratory tests, imaging studies, treatment options, and billing codes based on clinical presentation
━
Integrate via APIs into virtually any existing platform or health system infrastructure, a true plug-and-play architecture
━
Support and test medical students in clinical skills examinations, including OSCE (Objective Structured Clinical Examination) assessments
━
Deploy across multiple environments: telehealth platforms, voice assistants, nurse call centers, pharmacy kiosks, and health systems
━
Utilize across the “continuum of care” from patient intake, through real-time physician appointments through to post discharge/follow up care (see below)

The GLM is not a chatbot that answers health questions.


It is a clinical decision support engine that processes patient presentations the way a trained physician would: systematically, comprehensively, and with an understanding of how symptoms interact, how diseases present atypically, and how diagnostic uncertainty should be managed.


The company describes it as a system that “thinks like a doctor.”


Having been built by doctors with a combined century of clinical experience, that is not marketing language.


It is an accurate description of the design philosophy.

A platform built for the full patient journey.

Most healthcare AI companies solve one narrow problem. A symptom checker. A documentation tool or a scheduling assistant.

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has built an integrated platform designed to support the entire continuum of care, from the moment a patient first engages with the health system to the follow-up care that determines whether an acute episode becomes a chronic condition.

Patient Intake

An AI Assistant for the front door

An AI Assistant, deployable for example as either a voice agent or text-based chatbot, to handle initial patient triage, smart doctor-patient matching, and automated appointment booking.


It can conduct initial care assessments and feed structured clinical data directly into the patient chart, eliminating the redundant data entry that currently consumes so much of a physician’s time.

Patient Visit

Clinbot, powered by the GLM

During a clinical encounter, it’s physician supporting platform (Clinbot), powered by the GLM, provides AI-driven diagnostic support, guiding questioning, surfacing relevant clinical information, suggested tests and generating documentation in real time.


If integrated via APIs into an EMR (Electronic Medical Record), it enables systems to capture the full encounter, integrated with the AI systems so that the documentation burden on the physician is dramatically reduced. Video, chat, and live appointment formats are all supported.

Patient Follow-Up

The phase that's usually dropped

After the visit, the platform can be used to manage chronic condition follow-up, future appointment scheduling, medication reminders, and physician follow-up workflows, the phase of care that is most commonly dropped in a fragmented healthcare system and most predictive of patient outcomes.


The platform is fully brandable, multilingual, scalable, and designed to sit behind the client’s firewall, meaning health systems and physician groups can deploy it as their own, white-labeled technology without compromising patient privacy or data security.

This is not a collection of disconnected tools. It is a unified AI healthcare operating system that can be deployed by a physician group, a hospital system, a pharmacy chain, or a payer, and configured for a variety of clinical scenarios.

Real traction. Real patients. Real revenue. 

In a sector littered with companies that have impressive decks and empty waiting rooms, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK)‘s operational track record to date stands out.

Patients served
0 K
Active physicians
0 +
Virtual resolution[6]
0 %

Canada: a proven model at scale. 

In Canada, the Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) platform has already demonstrated that its model works at meaningful scale:

━
More than 700,000 patients have been served on the platform
━
More than 300 physicians are active on the platform, across specialties from family medicine to emergency care
━
Operations span three provinces, including Alberta, British Columbia, and Ontario
━
97% of patients seen on the platform were managed entirely virtually, without requiring a referral to in-person care, based on outcomes data from a 12,000-patient sample across a three-month period [6]

That last figure deserves emphasis. A 97% virtual resolution rate is not just an impressive statistic; it is a direct measure of clinical effectiveness.


It means that the platform is not triaging patients to unnecessary in-person care, because the platform can handle complexity.

It is resolving complex clinical presentations virtually, at scale, with outcomes that match or exceed what a traditional in-person system delivers.

United States: a multi-payer strategy unlocking millions of covered lives. 

In the United States, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has methodically built the infrastructure that competitors cannot easily replicate quickly.


Building a functional digital health practice in the US is genuinely hard, it requires a sequence of steps that takes years and carries no guarantee of success:

━
Securing payer contracts: 8 to 15+ months per payer, with no certainty of approval
━
Credentialing physicians: 3 to 6 months per physician
━
Setting up billing infrastructure: 1 to 2 months
━
Building patient growth: an ongoing process that begins only after all of the above is in place

The total estimated time to replicate what Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has already built in the US is 2.5+ years, with competitors facing ~18 to 24+ months to match the company’s tech stack, payer relationships, credentialing network, and revenue operations, with no guarantee of success even then.

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is currently pursuing three simultaneous payer verticals in the US: Medicare Advantage, Commercial insurance, and Medicaid. The Company also has focused initially on California and New York, being two of the largest and most complex populations.

This multi-payer strategy gives the platform access to an estimated 21 million+ covered lives across its current network, with additional plans representing millions more members in active discussion.

New York

New York represents one of the most significant healthcare markets in the world, and Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is actively operating there. The company has access to approximately 9.9 million patients (including 6.3 million on Medicare and Medicaid and 3.5 million members through in-network employer and commercial insurance plans).

In partnership with the CVS Health Foundation, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has launched a Healthy Aging Program in New York City supported by a $1 million grant, targeting connection of 700+ patients to primary, urgent, and mental health care by Q2 2026.[7]

California

In California, the company has treated more than 6,000 patients to date and has access to approximately 8.2 million patients (including 5.35 million on Medicare and Medicaid and 2.8 million members through in-network employer and commercial insurance plans).

A physician network that competitors 
cannot easily match.

While many digital health companies struggle to recruit and retain qualified physicians, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has built a network of clinicians with credentials from some of the most respected medical institutions in the world: Harvard, Stanford, Johns Hopkins, UCSF, and Geisinger, among others.

Credentialed in US
0
MDs actively seeing patients
In credentialing pipeline
0
Additional MDs in process

Currently, 15 MDs are credentialed and actively seeing patients in the US, with 35 more in the credentialing pipeline.


The depth of clinical leadership at Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is unusual for a company of its size. The physician roster includes regional leads for British Columbia, Alberta, Ontario, Atlantic Canada, California, Maryland and New York; specialist leads in psychiatry, pediatrics, psychotherapy, substance use services, and addictions medicine; and quality improvement leads credentialed at Berkeley and NOSM.


This is not a skeleton staff. It is a functioning clinical organization.

Financial profile: early-stage revenues with 
high-margin foundations.

As of December 1, 2025, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is generating $2.05 million in Annual Recurring Revenue across three distinct revenue streams:

Revenue Stream ARR Mechanism
Direct to Consumer $1.66M Generated through physician appointments at an average of 17% fee per Canadian appointment and a flat $18 USD fee per US appointment.
Partnerships $279K From pharmacies, allied health partners, and independent provider associations, with a $250 setup fee, $250 per month for support, and $3,000 for device-enabled kiosk stations.
Platform (MD Subscriptions) $105K Monthly fees paid by physicians on the platform, ranging from $25 to $75 per month depending on specialty and geographic location.

In Q3 2025, the company generated ~$500,000 in revenue at an 88% gross margin, a margin profile that reflects the fundamental economics of a software-powered healthcare platform, where the marginal cost of delivering additional care through AI infrastructure is dramatically lower than traditional healthcare delivery models.[8]


The revenue base today represents the early commercialization phase of a platform that has been built, validated, and proven over nearly a decade.


Subject to the successful implementation of the announced contracts, it is envisioned that significant growth will come as additional payer contracts go live in 2026 (US currently represents <5% of the company’s revenues), resulting in US patient volume scaling with the growing physician network. Further opportunities exist, through potential enterprise partnerships with health systems and pharmacy chains, expanding the GLM’s reach into new deployment contexts.

The competitive landscape: why Rocket Doctor AI stands apart.

The healthcare AI space is attracting significant capital, and several well-funded companies are building products in adjacent areas.


Understanding where Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) sits relative to those companies clarifies the uniqueness of what has been built.

Company Market Cap / Valuation Brief Highlight
ADA HEALTH $600M+ Symptom assessment app with 1.2 million users and 12 million assessments.
OpenEvidence $12B secured a $250 million Series D funding round in January 2026 that doubled its valuation to approximately $12 billion. The platform synthesizes medical research and treatment suggestions for clinicians, a powerful tool for research-oriented physicians, but at this time it is not an integrated virtual care or real-time diagnostic support platform.[10]
HYPOCRATIC AI $3.5B Reached approximately $3.5 billion valuation following its $126 million Series C in October 2025. It focuses on safety-focused generative AI agents (chatbots) for healthcare, as opposed to the full-stack platform that Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has built.[11]
SoundHound AI ~$6.6B (NASDAQ: SOUN) has a market cap of approximately $6.6 billion and is a conversational AI leader just entering healthcare, with an estimated 15 to 25% of revenue coming from the healthcare sector. It is a general-purpose voice AI company adapting to healthcare, as opposed to a healthcare company that built voice AI to support its clinical decision support engine.[12]
ROCKET DOCTOR AI ~$58M (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) occupies a position: a physician-designed platform that combines clinical intelligence (GLM), virtual care delivery (the physician network and telemedicine infrastructure), and voice AI. All in one trusted, integrated ecosystem with nearly a decade of clinical development behind it and proven patient outcomes at scale. The company is not trying to win a single category. It is building the infrastructure layer that every category will eventually run on.

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) occupies a position: a physician-designed platform that combines clinical intelligence (GLM), virtual care delivery (the physician network and telemedicine infrastructure), and voice AI.


All in one trusted, integrated ecosystem with nearly a decade of clinical development behind it and proven patient outcomes at scale.


The company is not trying to win a single category. It is building the infrastructure layer that every category will eventually run on.

Leadership: built by
doctors, led by operators.

Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, WKN: A41FSK) is not just built by software engineers pretending to understand medicine.

 

It’s designed by practicing physicians who live on the front lines every day and work “hand in glove” with their technology teams.

 

The experienced leadership team includes physicians with backgrounds from Johns Hopkins University, University of Toronto, University of California San Francisco, University of Calgary, University of Alberta, Harvard, Stanford, Berkeley, and Geisinger.

 

As well as deep expertise across clinical decision support, chronic disease management, virtual care, family medicine, emergency medicine, primary care, psychiatry, addiction medicine, pediatrics, quality improvement, and provider success.

Dr. Essam Hamza, MD, CCFP

CEO · Rocket Doctor AI Inc.
Experienced physician-entrepreneur: Primary care physician with 25+ years of medical experience and a proven track record building and scaling healthcare companies, including founding CloudMD Inc.
Proven scale operator: As a leader at CloudMD (2019–2022), helped drive growth from ~$4M in annual revenue and a small team to $100M+ in annual revenue with hundreds of employees and customers across North America.
Healthcare innovator & CEO: Early adopter of digital primary care and clinic automation in Canada; appointed CEO of Treatment.com AI in October 2023.

Dr. William Cherniak, MD, MPH, CCFP(EM)

Founder & CEO · Rocket Doctor Inc.

Emergency medicine & public health expert: Practicing emergency physician, University of Calgary Medical School graduate with an MPH from the Johns Hopkins Bloomberg School of Public Health, where he was a Sommer Scholar and NIH/NCI Global Cancer Control Fellow.

Global health leadership: Co-Founder and Board Chair of Bridge to Health Medical and Dental, a Canadian charity and U.S. 501(c)(3) that has trained 800+ healthcare workers and delivered free care to 50,000+ patients across East Africa, the Middle East, and Latin America.

Academic & clinical educator: Faculty appointments at the University of Toronto (Emergency Medicine), Johns Hopkins Bloomberg School of Public Health, and prior teaching roles at USC Keck School of Medicine and Northwestern University.

Dr. Kevin Peterson, MD, MPH, FRCS(Ed), FAAFP

Co-Founder & CMO · Rocket Doctor AI

National healthcare and research leader: Primary care physician specializing in chronic disease management, diabetes, bioinformatics, and clinical trials; former Vice President of Primary Care at the American Diabetes Association and Professor Emeritus at the University of Minnesota Medical School.

Proven NIH & AHRQ research authority: Principal Investigator on numerous NIH-funded studies and former National Director of the AHRQ PBRN Resource Center, supporting research across 17,000+ primary care practices and helping build a national electronic primary care research infrastructure.

Medical AI innovator: Co-Founder of Treatment.com, with 25+ years translating research into community clinical practice; Fellow of the American Academy of Family Physicians and the Royal College of Surgeons (Edinburgh), and developer of multiple medical technologies.

Richard Atkins

COO · Rocket Doctor AI

Seasoned commercial and M&A leader: 30+ years of experience in international sales, strategic partnerships, executive management, and M&A, including multiple multi-million-dollar transactions with leading health-tech and software companies.

Deep healthcare and technology expertise: Background spanning enterprise software and infrastructure (cloud, data centers, CRM, analytics, omnichannel contact centers), with the past 15+ years focused on healthcare across the continuum of care and clinical decision support.

Digital health and interoperability specialist: Hands-on experience with telehealth, healthbots, symptom checkers, teletriage services, managed PACS/RIS and LIMS, and EMR/billing systems, including HL7/FHIR interoperability across public and private healthcare systems.

Harry Cherniak

Co-Founder, COO & Privacy Officer · Rocket Doctor

Corporate strategy, legal, and M&A expert: Holds an HBA (Ivey Business School), MSc (London School of Economics), and JD (University of Toronto); former corporate lawyer at Torys LLP with deep experience in complex M&A and corporate transactions.

Blue-chip transaction experience: Advised on multi-billion-dollar deals involving leading institutions including Scotiabank, Canadian Tire, Sun Life, Manulife, Rogers Communications, Bell Canada, and private equity firms across acquisitions, financings, and shareholder arrangements.

Public policy and international perspective: Professional experience in London working with Jon Trickett MP, providing exposure to UK public policy and business regulation at the national level.

Capital structure and current metrics. 

As of April 2026, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) reflects an early-stage capital structure with meaningful upside potential relative to current market pricing. Recent US-focused press activity adds to the investment case, with execution being the determining factor.[13]


For context, comparable AI healthcare companies at similar or earlier stages of commercial development have attracted valuations measured in the billions.

OpenEvidence reached a $12 billion valuation. Hippocratic AI reached $3.5 billion. SoundHound AI, which is only partially in healthcare, carries a market cap above $6 billion. Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK), with a proven platform, established patient base, growing revenue, 88% gross margins, and a decade of proprietary clinical AI development behind it, is being valued at a fraction of those figures.

That gap is not a permanent feature of the landscape. It is a window, and windows in early-stage technology investing do not stay open indefinitely.

Why now may be the right moment. 

Several converging forces are creating a specific window of opportunity for Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) that did not exist two years ago and may not exist two years from now.

First — payer acceptance has reached a structural inflection point.

Medicare and Medicaid have expanded telehealth coverage in ways that were unimaginable before the pandemic, and those expansions are increasingly being made permanent.

 

The multi-payer network that Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has spent years building is now positioned to generate meaningful volume as each additional plan goes live. This is based on the number of members who can potentially utilize Rocket Doctor’s “in network” position is in excess of 19 million.

Second — the AI moment in healthcare is real and accelerating.

The investment being deployed into AI healthcare broadly, OpenEvidence’s $250 million raise in January 2026, Hippocratic AI’s $126 million Series C in October 2025, the flood of capital going into every adjacent sector, is validating the space and creating the conditions under which Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) ‘s proprietary GLM and integrated platform can become increasingly recognized as category-defining assets.[14]

Third — the domestic supply crisis in North American healthcare is not improving.

It is getting worse.

 

Physician burnout, administrative overload, and access inequality are accelerating in ways that make AI-powered care delivery not a nice-to-have but a structural necessity. [15]


The tailwinds for this company are systemic and unlikely to reverse.

And fourth — the competitive moat

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has built, nearly a decade of clinical AI development, 25,000+ hours of clinician input, 10,000+ expert medical reviews, 700,000+ patients served, payer contracts in place, physicians credentialed, billing infrastructure operational, is genuinely difficult to replicate.


The company has spent years doing the hard work that competitors are only now beginning to attempt.

The bottom line.

Healthcare is one of the largest industries on earth, and it is being transformed by AI faster than almost anyone predicted.

The companies that will define the next chapter of that transformation are the ones that built clinical intelligence from the ground up, not the ones trying to retrofit general-purpose AI into clinical workflows.


Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has been building that clinical intelligence since 2016.


It has proven the model at scale in Canada.


It is building the payer infrastructure, the physician network, and the technical platform required to scale it in the United States. The platform is currently generating consistent revenue with high gross margins.


At its current market capitalization, there appears to be a disconnect between the company’s valuation and the fundamental value of the technology suite.

The healthcare system is broken. Curated AI (clinicians and AI combining in decision making) is the only viable fix.

And one physician-built company is already building it: Rocket Doctor AI!

Quick Links To Preferred Brokerages

Stock Information

Rocket Doctor AI Inc.

Canadian Securities Exchange

AIDR

OTC Markets

AIRDF

WKN (Germany)

A41FSK

Key Metrics

Annual Recurring Revenue

$2.05M

Q3 2025 revenue

~$500K

Gross margin

88%

Patients served

700K+

Active physicians

300+

Virtual resolution

97%

Investor Presentation
Stay up to date and subscribe to our investor newsletter.

"Rocket Doctor AI: A platform built for the full patient journey."

Disclaimers

Paid Advertisement

This communication is a paid advertisement and is not a recommendation to buy or sell securities. Danayi Capital Corp. (collectively with its owners, managers, employees, and assigns “Danayi Capital Corp.”) has been paid $125,000 United States dollars (US$) by Rocket Doctor AI Inc. (plus applicable taxes) for an ongoing marketing campaign including this article among other things. This compensation is a major conflict with our ability to be unbiased. This communication is for entertainment purposes only. Never invest purely based on our communication. Danayi Capital Corp. owns and operates the website www.wallstreetlogic.com and its associated landing pages.

Share Ownership

The owner of Danayi Capital Corp. may be buying and selling shares of this issuer for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

Not an Investment Advisor

Danayi Capital Corp. and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation..

Always Do Your Own Research

Always consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Risk of Investing

Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.

Forward-Looking Statements and Legal Disclaimers — Please Read Carefully

This landing page contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to, among other things, expectations regarding the adoption, scalability, commercialization, and future performance of artificial intelligence–enabled healthcare platforms, revenue growth, payer integration, physician adoption, regulatory outcomes, and the Company’s business strategy and market opportunity.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or events to differ materially from those expressed or implied by such statements. Risks and uncertainties that could cause actual outcomes to differ include, but are not limited to: the risk that demand for digital or AI-enabled healthcare solutions does not increase as anticipated; that patients, physicians, payers, or healthcare systems may be slow to adopt or may reject AI-powered medical platforms; that regulatory, compliance, reimbursement, or licensing requirements may change or prove more restrictive than expected; that payer relationships, insurance coverage, or reimbursement rates may be delayed, reduced, terminated, or not expanded as anticipated; that technological developments or competing solutions may reduce the relevance or effectiveness of the Company’s platform; that artificial intelligence tools may fail to perform as expected or may encounter accuracy, safety, liability, or explainability challenges; that the Company may be unable to successfully integrate with electronic medical records, healthcare systems, or payer infrastructure; that operational, data security, privacy, or cybersecurity risks may arise; that physician recruitment, retention, or utilization may not scale as planned; that partnerships or grant-funded initiatives may not generate expected outcomes; that revenue growth, margins, or profitability may not be achieved; that the Rocket Doctor AI Inc. may be unable to raise sufficient capital to execute its business plans; or that management may be unable to successfully implement or scale the Company’s strategy.

Forward-looking statements are based on management’s current expectations, assumptions, and beliefs as of the date hereof and are subject to change. Readers are cautioned not to place undue reliance on forward-looking information. Danayi Capital Corp. undertakes no obligation to update or revise any forward-looking statements or information to reflect new events, circumstances, or changes in expectations, except as required by applicable law.

Non-GAAP Financial Metrics

Non-GAAP measure. This article contains financial measures not prepared in accordance with generally accepted accounting principles (referred to as Non-GAAP). Specifically, annual recurring revenue (“ARR”) should not be construed as alternatives to net income/loss determined in accordance with IFRS. ARR does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. The Company defines ARR as “the total value over the preceding twelve months of all recognized revenues in accordance with IFRS, plus all otherwise contracted for revenue commitments from customers, stemming from or related to all ongoing revenue sources.” The most directly comparable GAAP financial measure to ARR is revenue. Rocket Doctor AI Inc. believes that ARR is a meaningful financial metric for investors as it adjusts revenue to reflect amounts which Rocket Doctor anticipates recognizing as revenue from contracted agreements and provides a year-over-year comparison to assist in measuring revenue growth.

Additional Disclaimer

This publication is part of an advertising campaign for the company under discussion and is aimed at experienced and speculatively oriented investors. This review of Rocket Doctor AI Inc. should not be construed as an independent financial analysis or even investment advice, as there are significant conflicts of interest that may affect the objectivity of the preparers (see the following section “Disclosure of Interests and Conflicts of Interest and Conflict of Interest Prevention Policies”).

Legal Notices

Type of information

Marketing communication

Legal Notices

Danayi Capital Corp., a company incorporated in British Columbia, Canada.

Date of first creation

on or about February 1, 2025

Time of first creation

on or about 05:30AM PST

Creator of the marketing communication

Danayi Capital Corp.

Coordination with the issuer

Yes

Addressees

Danayi Capital Corp. makes the securities analysis available to all interested investment service providers and private investors at the same time.

Sources

Information sources of Danayi Capital Corp. are information of the issuer, domestic and foreign business press, information services, news agencies (e.g. Reuters, Bloomberg, Infront, etc.), analyses and publications on the Internet.

Scale of care

Valuations and investment judgments derived from them are prepared with the greatest possible care and taking into account all factors that are recognizably relevant at the respective time.

Disclosure of Interests and Conflicts of Interest, as well as Conflict of Interest Prevention Policies

Danayi Capital Corp. receives a fixed fee from Rocket Doctor AI Inc. for the distribution of the marketing communication.

Because other research houses and stock market letters can also discuss the value, there may be a symmetrical generation of information and opinion in the current recommendation period. Of course, it is important to note that Rocket Doctor AI Inc. is listed in the highest conceivable risk class for stocks. The company may not yet have any sales and is at an early-stage level, which is both attractive and risky. The company’s financial situation is still loss-making, which significantly increases the risks. Capital increases that become necessary could also lead to dilution in the short term, which could be to the detriment of investors. If the company does not succeed in tapping into further sources of finance in the next few years, insolvency and delisting could even be threatened.

Declaration of Release from Liability and Risk of Total Loss of Invested Capital

We would like to point out that equity investments are always associated with risk. Every transaction with warrants, leverage certificates or other financial products is even fraught with extremely high risks. Due to political, economic or other changes, there can be considerable price losses, in the worst case a total loss of the capital employed. With derivative products, the probability of extreme losses is at least as high as with small-cap shares, whereby the large domestic and foreign stocks can also suffer severe price losses up to a total loss. You should seek further advice before making any investment decision (e.g. from your bank or an advisor you trust).


Although the evaluations and statements contained in the analyses and market assessments of stock metrics have been prepared with reasonable care, we do not accept any responsibility or liability for errors, omissions or misstatements. This also applies to all representations, figures and assessments expressed by our interlocutors in the interviews. The entire risk arising from the use or performance of the Service and Materials remains with you, the reader. To the maximum extent permitted by applicable law, Danayi Capital Corp. shall not be liable for any special, incidental, indirect, or consequential damages (including, but not limited to, lost profits, business interruption, loss of business information, or any other pecuniary loss) arising out of the use of, or inability to use, the Service and Materials.

 

All statements in this report regarding Rocket Doctor AI Inc., other than statements of historical fact, should be construed as forward-looking statements that may not materially prove to be true due to significant uncertainties. The author’s statements are subject to uncertainties that should not be underestimated. There is no certainty or guarantee that the forecasts made will actually come true. Therefore, readers should not rely on the statements of stock metrics and should buy or sell securities only based on reading the report.
Users who make investment decisions or carry out transactions on the basis of the information displayed or ordered for Danayi Capital Corp. act entirely at their own risk.


The reader hereby assures that he uses all materials and content at his own risk and that Danayi Capital Corp. assumes no liability.


Danayi Capital Corp. reserves the right to modify, improve, expand or remove the content and materials without notice. Danayi Capital Corp. excludes any warranty for service and materials. The Service and Materials and the related documentation are provided to you “as is” without warranty of any kind, either express or implied. Including, but not limited to, implied warranties of merchantability, fitness for a particular purpose, or non-infringement.


The recommendations, interviews and company presentations published on this website fulfil advertising purposes without exception and are commissioned and paid for by third parties or the respective companies. For this reason, the analyses are not independent research studies.

 

There is no guarantee that the forecasts of the Company, the analyst or other experts and the management will actually come true. The performance of Rocket Doctor AI Inc. shares is therefore uncertain. As with any so-called microcap, there is also a risk of total loss.

 

The investor should follow the news closely and have the technical requirements for trading in penny stocks. The narrowness of the market, which is typical of the segment, ensures high volatility. Inexperienced investors and LOW-RISK investors are generally advised not to invest in shares of Rocket Doctor AI Inc. This analysis is aimed exclusively at experienced professional traders.

 

The author does not guarantee the completeness, timeliness or quality of the information provided. Liability claims against the author are excluded, as far as a negligent act is concerned. The author reserves the right to revise, supplement or delete parts of his statements.

Impressum (Required Information According to § 5 TMG)

Danayi Capital Corp.

Commercial Register

Address

550 – 800 West Pender Street, Vancouver, British Columbia, V6C 2V6, Canada

Represented by

Mehran Bagherzadeh

Phone

604-767-2983

Email

Mehran@danayi.co

References

  • [1] AARP. (2023, August 15). The cost of a wrong diagnosis. AARP. https://www.aarp.org/health/conditions-treatments/info-2023/cost-of-misdiagnosis.html
  • [2] Lagrotteria, L. (2024, November 11). Beating Administrative Burden — How Digital Health Tools Can Save Administrative Medicine. Healthy Debate. https://healthydebate.ca
  • [3] Grand View Research. (2024). AI in Healthcare Market Size, Share & Trends Analysis Report. grandviewresearch.com
  • [4] Global Market Insights. (2024). Telehealth Market Size & Share Report, 2024-2032. gminsights.com
  • [5] Rocket Doctor AI Inc. (February 2026). Investor Deck — February 2026. Global Library of Medicine. rocketdoctor.ai
  • [6] Rocket Doctor AI Inc. (February 2026). Investor Deck — February 2026. Canada Operations Data. Based on outcomes from a sample of 12,000 patients across the platform over a 3-month period.
  • [7] Rocket Doctor AI Inc. (February 2026). Investor Deck — February 2026. CVS Health Foundation Healthy Aging Program, New York City.
  • [8] Rocket Doctor AI Inc. (February 2026). Investor Deck — February 2026. Q3 2025 Key Financials. Unaudited figures as of December 1, 2025.
  • [9]
    Ada Health. (2024). Ada Health Company Overview. ada.com/about
  • [10] OpenEvidence. (January 2026). Series D Funding Announcement. $250 million Series D, valuation approximately $12 billion. openevidence.com
  • [11] Hippocratic AI (November 2025). Series C Funding Announcement. $126 million Series C, valuation approximately $3.5 billion.
  • [12] SoundHound AI, Inc. (NASDAQ: SOUN). Market capitalization data as of January 28, 2026. ir.soundhound.com
  • [13] Rocket Doctor AI Inc. (February 2026). Investor Deck — February 2026. Current Value Metrics.
  • [14] Patients for Patient Safety Canada. Diagnosis error is a huge patient safety problem. We need more proof. patientsforpatientsafety.ca
  • [15] The Physicians Foundation: 2025 State of America’s Physicians Survey. physiciansfoundation.org
No Result
View All Result

© 2024 Wallstreetlogic.com - All rights reserved.